Mutation of CEP72 Gene May Predispose Patients to Hepatotoxicity.

Autor:	Pham R; University of North Texas Health Science Center., Hoeft A; Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX., Roberts C; Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX., Hamby T; Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX., Maloy C; University of North Texas Health Science Center., Ray A; Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX.
Jazyk:	angličtina
Zdroj:	Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2020 Oct; Vol. 42 (7), pp. e634-e636.
DOI:	10.1097/MPH.0000000000001568
Abstrakt:	Drug toxicities during treatment of acute lymphoblastic leukemia play a pivotal role in influencing the outcome as certain toxicities may impair treatment compliance. Polymorphisms in CEP72 have been linked to increased incidence of vincristine-induced toxicities, namely peripheral neuropathy. We hypothesize that polymorphisms in the same gene may increase a patient's risk of developing hepatotoxicity when receiving potentially hepatotoxic agents during chemotherapy. This report describes hepatotoxicity that first developed during consolidation in a patient homozygous for the CEP72 risk alleles. Bilirubin levels normalized following dose reduction of 6-mercaptopurine. The patient continues to tolerate maintenance therapy at a reduced dose of 6-mercaptopurine.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu